

DAFTAR PUSTAKA

- Adams LA. Anstee QM. Tilg H. et al. Non-alcoholic Fatty Liver Disease and its Relationship with Cardiovascular Disease and Other Extrahepatic Diseases. *Gut*. 2017;66:1138-1153
- Ahmed MH. Barakat S. Almobarak AO. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Has the Time Come for Cardiologists to Be Hepatologists. *Journal of Obesity*. 2012
- Aisyah S. Balqis U. Friyan EK. Histopatologi Jantung Tikus Putih (*Rattus norvegicus*) Akibat Pemberian Minyak Jelantah. *Jurnal Medika Veterinaria*. 2014;8(1)
- Aprilianti F. Kawengian SES. Bolang ASL. Hubungan Asupan Lemak dengan Kadar hs-CRP Serum pada Mahasiswa Obes dan tidak Obes di Fakultas Kedokteran Universitas Sam Ratulangi Manado. *Jurnal e-Biomedik (eBM)*. Volume 1. Nomor 1. Maret 2013. hlm . 252-259
- Arab. J. P.. Arrese. M. and Trauner. M. (2018) ‘Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease’. *The Annual Review of Pathology: Mechanisms of Disease*. doi: 10.1146/annurev-pathol-020117-043617
- Arrese M. Cortés V. Barrera F. Nervi F. Nonalcoholic fatty liver disease. cholesterol gallstones. and cholecystectomy: new insights on a complex relationship. *Curr Opin Gastroenterol*. 2017. 33:000-000. doi: 10.1097/MOG.0000000000000416
- Bergheim. I.;Weber. S.; Vos.M.; Kramer. S.; Volynets. V.; Kaserouni. S.;McClain. C.J.; Bischoff. S.C. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: Role of endotoxin. *J. Hepatol*. 2008. 48. 983–992. [CrossRef] [PubMed]
- Bertolotti. M. *et al.* (2014) ‘Nonalcoholic fatty liver disease and aging: Epidemiology to management’. *World Journal of Gastroenterology*. 20(39). pp. 14185–14204. doi: 10.3748/wjg.v20.i39.14185.
- Bhat G. Baba CS. Pandey A. Kumari N. Choudhuri G. Life style modification improves insulin resistance and liver histology in patients with non-alcoholic fatty liver disease. *World J Hepatol* 2012;4:209–217
- Buechler C. Wanninger J. Neumeier M. Adiponectin. a key adipokine in obesity related liver diseases. *World journal of gastroenterology*. 2011; 17:2801–2811. [PubMed: 21734787]
- Buzzetti E. Pinzani M. Tsochatzis EA. 2016. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). *Metabolism* 65:1038–48
- Cai J. Zhang XJ. Ji YX. et al. Nonalcoholic Fatty Liver Disease Pandemic Fuels the Upsurge in Cardiovascular Diseases. *Circulation Research*. 2020;126:679-704.

- Carr. R. M.. Oranu. A. and Khungar. V. (2017) 'HHS Public Access'. 45(4). pp. 639–652. doi: 10.1016/j.gtc.2016.07.003.Nonalcoholic.
- Cavalca V. Cighetti G. Bamonti F. et al. Oxidative Stress and Homocysteine in Coronary Artery Disease. *Clin Chem*. 2001;47:887-892
- Chang Y. et al. Bidirectional Association between Nonalcoholic Fatty Liver Disease and Gallstone Disease: A Cohort Study. *J. Clin. Med.* 2018. 7. 458; doi: 10.3390/jcm7110458
- Chen Z. Yu Y. Cai J. et al. Emerging molecular targets for treatment of nonalcoholic fatty liver disease. *Trends Endocrinol Metab*. 2019;30:903-914
- Choi DH. Lee SJ. Kang CD. Park MO. Choi DW. Kim TS. et al. (2013) Nonalcoholic fatty liver disease is associated with coronary artery disease in Koreans. *World J Gastroenterol* 19: 6453–6457. doi: 10.3748/wjg.v19.i38.6453 PMID: 24151364
- Chowdhury. S. and Chakraborty. P. pratim (2017) 'Universal health coverage - There is more to it than meets the eye'. *Journal of Family Medicine and Primary Care*. 6(2). pp. 169–170. doi: 10.4103/jfmpc.jfmpc_103_17
- Crimmins. E.; Vasunilashorn. S.; Kim J K. and Alley D.; Biomarkers Related To Aging In Human Populations. *Adv Clin Chem*. Author manuscript; available in PMC 2018 May 07; 46: 161–216.
- De Piano A. de Mello MT. Sanches Pde L. da Silva PL. Campos RM. Carnier J. et al. Long-term effects of aerobic plus resistance training on the adipokines and neuropeptides in nonalcoholic fatty liver disease obese adolescents. *Eur J Gastroenterol Hepatol* 2012;24:1313-132
- Delvin. E. et al. (2014) *Pediatric non-alcoholic fatty liver disease*. *Journal of Medical Biochemistry*. doi: 10.2478/jomb-2014-0059.
- Dowman. J. K.. Tomlinson. J. W. and Newsome. P. N. (2010) 'Review Pathogenesis of non-alcoholic fatty liver disease'. (November 2009). pp. 71–83. doi: 10.1093/qjmed/hcp158.
- Duan Y. Zeng L. Zheng C. et al. Inflammatory links between high fat diets and diseases. *Front. Immunol*. 2018;9:1-10.
- Duseja. A. and Chalasani. N. (2013) 'Epidemiology and risk factors of nonalcoholic fatty liver disease (NAFLD)'. *Hepatology International*. 7(2013). pp. S755–S764. doi: 10.1007/s12072-013-9480-x.
- Eslam. M. et al. (2020) 'A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement'. *Journal of Hepatology*. European Association for the Study of the Liver. 73(1). pp. 202–209. doi: 10.1016/j.jhep.2020.03.039.

- F. S. Macaluso. M.Maida. and S. Petta. "Genetic background in nonalcoholic fatty liver disease: a comprehensive review." *World Journal of Gastroenterology.* vol. 21. no. 39. pp. 11088–11111. 2015.
- Festa A. et al. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. *Diabetes* 2002;51:1131–1137. [PubMed: 11916936]
- Fracanzani AL. Valenti L. Russello M. Miele L. Bertelli C. et al. (2012) Gallstone Disease is Associated with More Severe Liver Damage in Patients with Non-Alcoholic Fatty Liver Disease. *PLoS ONE* 7(7): e41183. doi: 10.1371/journal.pone.0041183
- Franca. A. et al. (2004) 'Evolution of Intrapulmonary Vascular Dilations in Cirrhosis [1]'. *Hepatology*. 39(5). p. 1454. doi: 10.1002/hep.20231.
- Franceschi. C. et al. (2018) 'Inflammaging: a new immune–metabolic viewpoint for age-related diseases'. *Nature Reviews Endocrinology*. Springer US. doi: 10.1038/s41574-018-0059-4.
- Francque SM. Graaff DVD. Kwanten WJ. Non-alcoholic Fatty Liver Disease and Cardiovascular risk: Pathophysiological Mechanism and Implications. *J Hepatol.* 2016
- Fu Z. Gilbert ER. Liu D. Regulation of insulin synthesis and secretion and pancreatic beta-cell dysfunction in diabetes. *Curr Diabetes Rev.* 2013; 9:25–53. [PubMed: 22974359]
- G. Musso. M. Cassader. E. Paschetta. and R. Gambino. "TM6SF2 may drive postprandial lipoprotein cholesterol toxicity away from the vessel walls to the liver in NAFLD." *Journal of Hepatology.* vol. 64. no. 4. pp. 979–981. 2016.
- Gala T. Herder C. Rutters F. Carstensen-Kirberg M. Huth C. Stehouwer C. Nijpels G. Schalkwijk C. Flyvbjerg A. Franks PW. et al. Association of changes in inflammation with variation in glycaemia, insulin resistance and secretion based on the KORA study. *Diabetes Metab Res Rev.* 2018;34(8):e3063.
- Gao B. Tsukamoto H. Inflammation in alcoholic and nonalcoholic fatty liver disease: Friend or foe? *Gastroenterology.* 2016; 150:1704–1709. [PubMed: 26826669]
- Garden OJ. et al. The Liver and Biliary Tract. Principles Practice Surgery. Churchill Livingstone Elsevier. 2012
- Genc H. Dogru T. Kara M. Tapan S. Ercin CN. Acikel C. et al. (2013) Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease. *Ann Hepatol* 12: 548–555. PMID: 23813132
- Giandomenico B. Ricci F. Mantini C. et al. Nonalcoholic fatty liver disease and cardiovascular disease phenotypes. *Sage Open Medicine.* 2020;8:1-15.
- Giorgio V. Miele L. Principessa L. Ferretti F. Villa MP. Negro V. Grieco A. Alisi A. Nobili V. Intestinal permeability is increased in children with non-alcoholic fatty liver

- disease, and correlates with liver disease severity. *Dig Liver Dis.* 2014; 46:556–560. [PubMed: 24631029]
- Hariri N. Thibault L. High-fat diet-induced obesity in animal models. *Nutr. Res. Rev.* 2010;23:270-299.
- He S. McPhaul C. Li JZ. Garuti R. Kinch L. Grishin NV. Cohen JC. Hobbs HH. A sequence variation (i148m) in pnpla3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. *J Biol Chem.* 2010; 285:6706–6715. [PubMed: 20034933]
- Herder C. Færch K. Carstensen-Kirberg M. Lowe GD. Haapakoski R. Witte DR. Brunner EJ. Roden M. Tabák AG. Kivimäki M. et al. Biomarkers of subclinical inflammation and increases in glycaemia, insulin resistance and beta-cell function in non-diabetic individuals: the Whitehall II study. *Eur J Endocrinol.* 2016;175(5):367–77.
- Ito. M.; Suzuki. J.; Tsujioka. S.; Sasaki. M.; Gomori. A.; Shirakura. T.; Hirose. H.; Ito. M.; Ishihara. A.; Iwaasa. H.; et al. Longitudinal analysis of murine steatohepatitis model induced by chronic exposure to high-fat diet. *Hepatol. Res.* 2007. 37. 50–57. [CrossRef] [PubMed]
- J. E. Lambert. M. A. Ramos-Roman. J. D. Browning. and E. J.Parks. “Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease.” *Gastroenterology.* vol. 146. no. 3. pp. 726–735. 2014.
- Jacobs. A.; Warda. A.S.; Verbeek. J.; Cassiman. D.; Spincemaille. P. An overview of mouse models of nonalcoholic steatohepatitis: From past to present. *Curr. Protoc. Mouse Biol.* 2016. 6. 185–200. [PubMed]
- Jannah BM. Isdadiyanto S. Sitasiwi AJ. Histopathological of White Rats Aorta Induced by High-Fat-Feed After Administered by Neem Leaf Ethanolic Extract. *Biosaintifika: Journal of Biology Education.* 2020;12(3):370-378
- Karaduman M. et al. Leptin, soluble interleukin-6 receptor, C-reactive protein and soluble vascular cell adhesion molecule-1 levels in human coronary atherosclerotic plaque. *British Society of Immunology. Clinical and Experimental Immunology* 2006. 143:452-457. doi: 10.1111/j.1365-2249.2006.03025.x
- Karampola M. Arigirou A. Hitoglou-Makedou A. Study on dietary constituents, hs-CRP serum levels and investigating of correlation between them in excess weight adolescents. *HIPPOKRATIA* 2019 23. 1: 3-8
- Kasper P. Martin A. Lang S. et al. NAFLD and cardiovascular diseases: a clinical review. *Clin Res Cardiol.* 2020
- Kohanski. R. A. (2017) *Biomarkers of Human Aging. Innovation in Aging.* doi: 10.1093/geroni/igx004.104.

- Kollathody S. et al. Association of hs-CRP with various components of metabolic syndrome. International Journal of Health and Rehabilitation Sciences. January 2016. Vol. 5 Issue 2. doi: 10.5455/ijhrs.0000000105
- Kuppan G. Anjana RM. Deepa M. Paramasivam P. Chandrakumar S. Kaliyaperumal V. et al. (2012) Inflammatory markers in relation to nonalcoholic fatty liver disease in urban South Indians. *Diabetes Technol Ther* 14: 152–158. doi: 10.1089/dia.2011.0213 PMID: 22149546
- Lau. J.K.; Zhang. X.; Yu. J. Animal models of non-alcoholic fatty liver disease: Current perspectives and recent advances. *J. Pathol.* 2017. 241. 36–44. [CrossRef] [PubMed]
- Lawrence P. F. Biliary Tract. Essential of General Surgery. Lippincot William & Wilkins. 2013
- Lee. J. et al. (2017) ‘High-normal levels of hs-CRP predict the development of non-alcoholic fatty liver in healthy men’. *PLoS ONE*. 12(2). pp. 1–12. doi: 10.1371/journal.pone.0172666.
- Lee. Y. et al. (2019) ‘Nonalcoholic Fatty Liver Disease in Diabetes . Part I: Epidemiology and Diagnosis’. pp. 31–45.
- Lonardo. A. et al. (2020) ‘History of nonalcoholic fatty liver disease’. *International Journal of Molecular Sciences*. 21(16). pp. 1–38. doi: 10.3390/ijms21165888.
- Longato. L. Nonalcoholic fatty liver disease (NAFLD): A tale of fat and sugar? *Fibrogenesis Tissue Repair* 2013. 6. 14. [CrossRef] [PubMed]
- Lowette. K.; Roosen. L.; Tack. J.; Vanden Berghe. P. Effects of high-fructose diets on central appetite signaling and cognitive function. *Front. Nutr.* 2015. 2. 5. [CrossRef] [PubMed]
- Makki. K. et al. Adipose Tissue in Obesity-Related Inflammation and Insulin Resistance: Cells. Cytokines. and Chemokines. ISRN Inflammation Vol. 2013. Article ID 139239. 12 pages. <http://dx.doi.org/10.1155/2013/139239>
- Mamikutty. N.; Thent. Z.C.; Haji Suhaimi. F. Fructose-drinking water induced nonalcoholic fatty liver disease and ultrastructural alteration of hepatocyte mitochondria in male wistar rat. *BioMed Res. Int.* 2015. 2015. 895961. [CrossRef] [PubMed]
- McPherson K. Shields CA. Poudel B. et al. The impact of obesity as an independent risk factor for the development of renal injury : implications from rat models of obesity. *Am. J Physiol. Renal* 2019;316(2):F316-327.
- Milan-Mattos. J. C. et al. (2019) ‘Effects of natural aging and gender on pro-inflammatory markers’. *Brazilian Journal of Medical and Biological Research*. 52(9). pp. 1–10. doi: 10.1590/1414-431x20198392.

- Milić. S. and Štimac. D. (2012) ‘Nonalcoholic Fatty Liver Disease / Steatohepatitis : Epidemiology . Pathogenesis . Clinical Presentation and Treatment’. pp. 158–162. doi: 10.1159/000336669.
- Mirhoseini M. et al. Serum concentration of hs-CRP in obese individuals with and without metabolic syndrome and its association with parameters of metabolic syndrome. *J Renal Inj Prev.* 2018; 7(4): 297-300. doi: 10.15171/jrip.2018.65
- Mishra S. Yadav D. Gupta M. et al. A study of carotid atherosclerosis in patients with non-alcoholic fatty liver disease. *Indian J Clin Biochem.* 2013;28:79-83
- Mohamed AA. et al. Role of Serum Adiponectin. IL-6 and Hs CRP in Nonalcoholic Fatty Liver Egyptian Patients. *International Journal of Biochemistry Research & Review.* 4(6): 493-504. 2014.
- Mohamed AA. Shousha WG. Shaker O. et al. Role of Serum Adiponectin. IL-6 and hsCRP in Nonalcoholic Fatty Liver Egyptian Patients. *International Journal of Biochemistry Research & Review.* 2014;4(6):493-504
- Ndumele CE. Nasir K. Conceicao RD. Carvalho JA. Blumenthal RS. Santos RD. (2011) Hepatic steatosis. obesity. and the sindroma metabolik are independently and additively associated with increased systemic inflammation. *Arterioscler Thromb Vasc Biol* 31: 1927–1932. doi: 10.1161/ATVBAHA.111.228262 PMID: 21546603
- Neuman MG. Malnick S. Maor Y. Nanau RM. Melzer E. Ferenci P. et al. Alcoholic liver disease: Clinical and translational research. *Exp Mol Pathol.* 2015;99(3):596-610.
- Nigam P. Bhatt SP. Misra A. Vaidya M. Dasgupta J. Chadha DS. (2013) Non-alcoholic fatty liver disease is closely associated with sub-clinical inflammation: a case-control study on Asian Indians in North India.
- Noh BR. Koh YH. Kim JB. Song MG. Lee DA. Yu HK. Associations between Non-Alcoholic Fatty Liver and Gallbladder Polyps in Health Screen Examinees. *Korean J Fam Pract.* 2017;7(1):86-91. <https://doi.org/10.21215/kjfp.2017.7.1.86>
- Oni ET. Agatston AS. Blaha MJ. et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? *Atherosclerosis.* 2013;230:258-267
- P. Dongiovanni. S. Petta. C. Maglio et al.. “Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis fromcardiovascular disease.” *Hepatology.* vol. 61. no. 2. pp. 506–514. 2015.
- P. Pingitore. C. Pirazzi. R. M. Mancina et al.. “Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function.” *Biochimica et Biophysica Acta—Molecular and Cell Biology of Lipids.* vol. 1841. no. 4. pp. 574–580. 2014.

- Page KA. Chan O. Arora J. Belfort-Deaguiar R. Dzuira J. Roehmholdt B. Cline GW. Naik S. Sinha R. Constable RT. Sherwin RS. Effects of fructose vs glucose on regional cerebral blood flow in brain regions involved with appetite and reward pathways. *Jama.* 2013; 309:63–70. [PubMed: 23280226]
- Palmeri ML. Wang MH. Rouze NC. Abdelmalek MF. Guy CD. Moser B. et al. Noninvasive evaluation of hepatic fibrosis. *Clujul Medical Vol.* 91. No. 2. 2018: 147-150 using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. *J Hepatol.* 2011;55:666-672.
- Panichi V. Migliori M. De Pietro S. Taccolla D. Andreini B. Metelli MR. Giovannini L. Palla R. The link of biocompatibility to cytokine production. *Kidney Int Suppl.* 2000 Aug;76:S96-103. doi: 10.1046/j.1523-1755.2000.07612.x. PMID: 10936805.
- Park K. Steffes M. Lee DH. Himes JH. Jacobs DR. Association of inflammation with worsening HOMA-insulin resistance. *Diabetologia.* 2009;52(11):2337–44.
- Pearson TA. Mensah GA. Alexander RW. et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. *Circulation.* 2003;107(3): 499-511.
- Petersen KF. Dufour S. Hariri A. et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. *N Engl J Med* 2010;362:1082–1089
- Plomgaard P. Bouzakri K. Krogh-Madsen R. Mittendorfer B. Zierath JR. Pedersen BK. Tumor necrosis factor-alpha induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. *Diabetes.* 2005;54:2939–2945.
- Prasetya. I. B. *et al.* (2017) ‘Prevalence and Profile of Fibrosis in Diabetic Patients with Non-alcoholic Fatty Liver Disease and the Associated Factors’. *Acta medica Indonesiana.* 49(2). pp. 91–98.
- Puri K. Nobili V. Melville K. Corte CD. Sartorelli MR. Lopez R. et al. Serum bilirubin level is inversely associated with nonalcoholic steatohepatitis in children. *J Pediatr Gastroenterol Nutr.* 2013;57:114-118.
- Puri. P. and Sanyal. A. J. (2012) ‘Nonalcoholic fatty liver disease: Definitions. risk factors. and workup’. *Clinical Liver Disease.* 1(4). pp. 99–103. doi: 10.1002/cld.81.
- R. M. Mancina. P. Dongiovanni. S. Petta et al.. “The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent.” *Gastroenterology.* vol. 150. no. 5. pp. 1219–1230. 2016.
- Riani. R. I.. Purnomo. H. D. and Muis. S. F. (2017) Food Intake and Visceral Fat Deposition are Risk Factors of Incidence and Severity of Non-Alcoholic Fatty Liver Disease’.

- Journal of Biomedicine and Translational Research.* 3(2). p. 37. doi: 10.14710/jbtr.v3i2.1810.
- Ridker PM. Cushman M. Stampfer MJ. Tracy RP. Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. *N Engl J Med.* 1997; 336:973–979. [PubMed: 9077376]
- Rochlani Y. Pothineni NV. Kovelamudi S. Mehta JL. Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. *Ther Adv Cardiovasc Dis.* 2017. Vol. 11(8) 215-225. doi: 10.1177/1753944717711379
- Rodriguez-Hernandez H. Simental-Mendia LE. Rodriguez-Ramirez G. Reyes-Romero MA (2013) Obesity and inflammation: epidemiology, risk factors, and markers of inflammation. *Int J Endocrinol* 2013: 678159. doi: 10.1155/2013/678159 PMID: 23690772
- Rother RP. Rollins SA. Mojzik CF. Brodsky RA. Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. *Nat Biotechnol.* 2007 Nov;25(11):1256-64. (Pubmed)
- S. He. C. McPhaul. J. Z. Li et al.. “A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis.” *The Journal of Biological Chemistry.* vol. 285. no. 9. pp. 6706–6715. 2010.
- S. S. Lee. Y.-S. Byoun. S.-H. Jeong et al.. “Role of the PNPLA3 I148M polymorphism in nonalcoholic fatty liver disease and fibrosis in Korea.” *Digestive Diseases and Sciences.* vol. 59. no. 12. pp. 2967–2974. 2014.
- Saklayen MG. The Global Epidemic of the Metabolic Syndrome. *Current Hypertension Reports.* 2018 (20:12). <https://doi.org/10.1007/s11906-018-0812-z>
- Sanches. S.C.L.; Ramalho. L.N.Z.; Augusto. M.J.; da Silva. D.M.; Ramalho. F.S. Nonalcoholic steatohepatitis: A search for factual animal models. *BioMed Res. Int.* 2015. 2015. 1–13. [CrossRef] [PubMed]
- Sellmann. C.; Priebs. J.; Landmann. M.; Degen. C.; Engstler. A.J.; Jin. C.J.; Garttner. S.; Spruss. A.; Huber. O.; Bergheim. I. Diets rich in fructose, fat or fructose and fat alter intestinal barrier function and lead to the development of nonalcoholic fatty liver disease over time. *J. Nutr. Biochem.* 2015. 26. 1183–1192. [CrossRef] [PubMed]
- Sepehrimanesh M. Niknam R. Ejtehadi F. Fattahi MR. Safarpour A. Association Between Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome with Gallstone Disease. South Iran: A Population-Based Study. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy* 2020: 13 1449-1458. <http://doi.org/10.2147/DMSO.S246949>
- Sjamsuhidajat. R.. & D Jong. W. Buku Ajar Ilmu Bedah Edisi. Penerbit Buku Kedokteran ECG 2005; 2.18.
- Sookoian S. Pirola CJ. Nonalcoholic fatty liver disease is strongly associated with carotid

- atherosclerosis: a systematic review. *J Hepatol.* 2008;49:600-607
- Spruss. A.; Kanuri. G.; Wagnerberger. S.; Haub. S.; Bischoff. S.C.; Bergheim. I. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. *Hepatology* 2009. 50. 1094–1104. [CrossRef] [PubMed]
- Sullivan S. Implications of diet on nonalcoholic fatty liver disease. *Curr Opin Gastroenterol.* 2010; 26:160–164. [PubMed: 20010099]
- Sun Q. Li J. Gao F. New insights into insulin: The anti-inflammatory effect and its clinical relevance. *World J Diabetes.* 2014;5(2):89-96. doi:10.4239/wjd.v5.i2.89
- Susantiningsih T. Obesity and stress oxydative. Juke UNILA. 2015. Maret 2015. 5(9). 89-93
- Tana C. Ballestri S. Ricci F. et al. Cardiovascular Risk in Non-Alcoholic Fatty Liver Disease: Mechanisms and Therapeutic Implications. *Int J Environ Res Public Health.* 2009;16:3104
- Tana C. et al. Cardiovascular Risk in Non-Alcoholic Fatty Liver Disease: Mechanisms and Therapeutic Implications. *Int. J. Environ. Res. Public Health.* 2019. 16m 3014; doi:10.3390/ijerph16173104
- Targher G. Bertolini L. Padovani R. et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. *Diabetes Care.* 2006;29:1325-1330
- Thorand B. et al. Sex differences in the prediction of type 2 diabetes by inflammatory markers: results from the MONICA/KORA Augsburg case-cohort study. 1984-2002. *Diabetes Care* 2007;30:854– 860. [PubMed: 17392546]
- Tillett WS and Francis T Jr. Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. *J Exp Med.* 1930. 52: 561-571
- Townsend. 2012. Essentials of Psychiatric Mental Nursing (4th ed). Philadelphia: F. A. Davis Company
- Trevaskis. J.L.; Griffin. P.S.; Wittmer. C.; Neuschwander-Tetri. B.A.; Brunt. E.M.; Dolman. C.S.; Erickson. M.R.; Napora. J.; Parkes. D.G.; Roth. J.D. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. *Am. J. Physiol. Gastrointest. Liver Physiol.* 2012. 302. G762–G772. [CrossRef] [PubMed]
- Van Herck. M. A.. Vonghia. L. and Francque. S. M. (2017) ‘Animal models of nonalcoholic fatty liver disease—a starter’s guide’. *Nutrients.* 9(10). pp. 1–13. doi: 10.3390/nu9101072.
- Vitro. I. and Safety. D. (2018) ‘NON-ALCOHOLIC FATTY LIVER DISEASE: AN UPDATE ON DIAGNOSIS Diagnosis Imaging methods for liver fibrosis Inflammatory markers’. 91(2). pp. 147–150. doi: 10.15386/cjmed-993.

- Wannamethee SG. et al. The metabolic syndrome and insulin resistance: relationship to haemostatic and inflammatory markers in older non-diabetic men. *Atherosclerosis* 2005;181:101–108. [PubMed: 15939060]
- Williams L. 2013. Clinically Oriented Anatomy. Wolters Kluwer. Pg. 277
- Wong CR. Lim JK. The Association Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease Outcomes. *Clinical Liver Disease*. 2018;12(2)
- Wongjarupong N. et al. Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: a systematic review and meta-analysis. *BMC Gastroenterology*. 2017. 17:149. doi: 10.1186/s12876-017-0696-4
- Y. Ritze. G. B'ardos. A. Claus et al.. “Lactobacillus rhamnosus GG Protects against non-alcoholic fatty liver disease in mice.” *PLoS ONE*. vol. 9. no. 1. Article ID e80169. 2014.
- Yki-Järvinen. H. (2014) ‘Non-alcoholic fatty liver disease as a cause and a consequence of sindroma metabolik’. *The Lancet Diabetes and Endocrinology*. 2(11). pp. 901–910. doi: 10.1016/S2213-8587(14)70032-4.
- Yu. J. et al. (2016) ‘The Pathogenesis of Nonalcoholic Fatty Liver Disease : Interplay between Diet . Gut Microbiota . and Genetic Background’. 2016.
- Jarukamjorn K. et al. (2016) A High-Fat. High-Fructose Diet Induces Antioxidant Imbalance and Increases the Risk and Progression of Nonalcoholic Fatty Liver Disease in Mice. *Scientifica*
- Horne RG. et al. High Fat-Hight Fructose Diet-Induced Changes in the Gut Microbiota Associated with Dyslipidemia in Syrian Hamsters. *Nutrients*. 2020;12(3557)
- Lozano I. et al. High-fructose and high-fat diet-induced disorders in rats: impact on diabetes risk. hepatic and vascular complications. *Nutrition & Metabolism*. 2016;13:15
- Ardiansyah SA. et al. Uji Aktivitas Penurunan Indeks Obesitas dari Ekstrak Etanol Biji Kopi Hijau Robusta terhadap Tikus Putih Jantan Galur Wistar. *Jurnal Sains dan Teknologi Farmasi Indonesia*. 2019;8(2)





REKOMENDASI PERSETUJUAN ETIK

Nomor : 175/UN4.6.4.5.31/ PP36/ 2021

Tanggal: 17 Maret 2021

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

| | | | | |
|--|---|--|--|---|
| No Protokol | UH21020102 | | No Sponsor Protokol | |
| Peneliti Utama | dr. Mylda Pratiwi Ahmadwirawan | | Sponsor | |
| Judul Peneliti | Analisis Kadar Interleukin-6 (IL-6) dan High Sensitivity C-Reactive Protein(hs-CRP) di Serum dan Histopatologi Jaringan Jantung Pada Tikus Dengan Model Non-Alcoholic Fatty Liver Disease (NAFLD) | | | |
| No Versi Protokol | 1 | | Tanggal Versi | 19 Februari 2021 |
| No Versi PSP | | | Tanggal Versi | |
| Tempat Penelitian | Laboratorium Entomologi Fakultas Kedokteran Universitas Hasanuddin Makassar | | | |
| Jenis Review | <input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal | | Masa Berlaku 17 Maret 2021 sampai 17 Maret 2022 | Frekuensi review lanjutan |
| Ketua Komisi Etik Penelitian Kesehatan FKUH | Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K) | |  Tanda tangan |  |
| Sekretaris Komisi Etik Penelitian Kesehatan FKUH | Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K) | |  Tanda tangan |  |

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan